3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Leukemia, Myeloid, Acute
19
Lymphoma
17
Lymphoma, Large B-Cell, Diffuse
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Lymphoma, Non-Hodgkin
14
Hodgkin Disease
13
Multiple Myeloma
12
Lymphoma, Mantle-Cell
12
Lymphoma, Follicular
12
Carcinoma, Non-Small-Cell Lung
11
Breast Neoplasms
11
Leukemia, Lymphocytic, Chronic, B-Cell
9
Glioblastoma
9
Lymphoma, B-Cell, Marginal Zone
8
Burkitt Lymphoma
8
Brain Neoplasms
8
Sezary Syndrome
7
Neoplasms
7
Lymphoma, T-Cell, Cutaneous
7
Leukemia
7
Congenital Abnormalities
7
Unspecified Adult Solid Tumor, Protocol Specific
6
Recurrence
6
Neuroblastoma
6
Mycosis Fungoides
6
Lymphoma, Large-Cell, Immunoblastic
6
Lymphoma, Large-Cell, Anaplastic
6
Breast Neoplasms, Male
6
Sarcoma
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Interventions
Pemetrexed
23
Cisplatin
19
Nivolumab
8
Gemcitabine
7
Ipilimumab
6
Carboplatin
6
pembrolizumab
4
Bevacizumab
4
tazemetostat
3
durvalumab
3
Fluorouracil
3
Drug Therapy
3
spartalizumab
2
olaparib
2
niraparib
2
budigalimab
2
belinostat
2
anetumab ravtansine
2
amatuximab
2
Vinorelbine
2
Radiotherapy, Intensity-Modulated
2
Paclitaxel
2
PM 01183
2
Oxaliplatin
2
Imatinib Mesylate
2
Everolimus
2
Erlotinib Hydrochloride
2
Doxorubicin
2
Cyclophosphamide
2
venetoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Mesothelioma
×
Vorinostat
×
Clear all
NCT00128102
2020-10-26
MK-0683-014
Merck Sharp & Dohme LLC
Phase 3
Completed
661 enrolled
18 charts